Adipotide (Prohibitin-TP01)

🔹 What is Adipotide (Prohibitin-TP01)?

Class: Peptidomimetic compound with a genuinely different mechanism from most other weight-management compounds covered on this site. Mechanism:

• Most fat-loss peptides on this site work by signaling fat cells to mobilize and metabolize stored fat, or by acting on appetite and satiety pathways.
• Adipotide does neither. It targets a protein called prohibitin, expressed on the surface of blood vessels that specifically supply white adipose tissue.
• By binding prohibitin on those vessels, adipotide triggers apoptosis — programmed cell death — in the blood vessels feeding fat tissue. The fat tissue itself then regresses because its blood supply is cut off, not because the fat cells were signaled to release their contents.
• This is a fundamentally more aggressive, structurally destructive mechanism than the receptor-signaling approach used by GLP-1 drugs, GH secretagogues, or lipotropic blends elsewhere on this site.

Why it generates interest: Animal studies, including in primates, showed dramatic reductions in fat mass. That result is genuinely notable and is the reason this compound comes up in research and biohacking conversations at all.

Why it deserves real caution: The same studies and subsequent research also raised meaningful concerns about kidney toxicity. This is not a theoretical or boilerplate safety caveat — it’s a documented signal in the animal literature, and one of the central reasons adipotide has not advanced toward legitimate human clinical development the way many other peptides on this site have. The mechanism itself — deliberately inducing apoptosis in blood vessels — is not a “soft” biological signal, and it is reasonable to expect off-target effects on vasculature elsewhere in the body, including the kidneys, which are especially vascular-dense organs.

Bottom line: The risk profile here is meaningfully different from the rest of this encyclopedia. This is a research compound with a real, documented toxicity signal, not a wellness protocol with an established margin of safety. Self-directed human use carries meaningfully higher risk than most peptides covered on this site, and that risk should be weighed seriously rather than treated as routine.

---

🔹 Dosage — Why We’re Not Presenting a Confident Protocol Unlike most entries on this site, we are intentionally not laying out a detailed “example protocol” here. Reported doses circulating in research and enthusiast contexts vary widely and are drawn from animal studies rather than validated human dosing standards. Given the documented kidney toxicity signal, presenting a specific human dose here would imply a level of confidence and safety margin that the actual data does not support.

What is known in general terms:

• Research use has been via subcutaneous injection.
• Animal study dosing and duration varied considerably by model and objective, and does not translate cleanly to a validated human protocol.
• Oral use is not a viable route — as a peptidomimetic, it would not survive GI digestion intact.

---

🔹 Cycle Length There is no established, validated human cycle length for adipotide. Animal studies used defined dosing windows for research purposes, but these do not constitute a human safety protocol, and extrapolating cycle length from animal data would be misleading.

---

✅ Educational Integration Example We are deliberately not providing an example protocol for this compound. Given the documented toxicity concerns, any specific dosing example here would risk being read as an implicit endorsement of self-directed use, which is not something we want to suggest for this particular compound.

---

🔹 Stacking Strategy We are not presenting stacking recommendations for adipotide. Its mechanism — destruction of the vascular supply to fat tissue — is not one that should be layered with other compounds outside of a clinical or formal research setting, and doing so would compound an already meaningful risk profile without a clear basis for doing so safely.

Disclaimer: This entry is provided for educational and research awareness only, and is not a recommendation for use. Adipotide has a documented toxicity signal (particularly kidney-related) in the research literature, and its risk profile is meaningfully different from most other compounds on this site. Do not rely on any information here for self-directed dosing. Please consult with a qualified healthcare provider before considering any research use of this compound.